632 related articles for article (PubMed ID: 33212067)
1. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
Coronel-Martinez DL; Park J; López-Medina E; Capeding MR; Bonfanti AAC; Montalbán MC; Ramírez I; Gonzales MLA; Zambrano B; Dayan G; Chen Z; Wang H; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2022 Jun; 22(6):901-911. PubMed ID: 35364022
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
7. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
[TBL] [Abstract][Full Text] [Related]
9. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
[TBL] [Abstract][Full Text] [Related]
10. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
Tran NH; Chansinghakul D; Chong CY; Low CY; Shek LP; Luong CQ; Fargo C; Wartel TA; Sun S; Skipetrova A; Bouckenooghe A
Hum Vaccin Immunother; 2019; 15(10):2315-2327. PubMed ID: 30724660
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.
Park J; Archuleta S; Oh MH; Shek LP; Jin J; Bonaparte M; Fargo C; Bouckenooghe A
Hum Vaccin Immunother; 2020 Mar; 16(3):523-529. PubMed ID: 31464558
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
Dayan GH; Thakur M; Boaz M; Johnson C
Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
[TBL] [Abstract][Full Text] [Related]
14. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
[TBL] [Abstract][Full Text] [Related]
15. Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
Coronel D; García-Rivera EJ; Rivera DM; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Wang H; Pagnon A; Jantet-Blaudez F; Peñalosa LAR; Dayan G; Zambrano B; DiazGranados CA; Noriega F
Pediatr Infect Dis J; 2020 Oct; 39(10):961-968. PubMed ID: 32932330
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
Leo YS; Wilder-Smith A; Archuleta S; Shek LP; Chong CY; Leong HN; Low CY; Oh ML; Bouckenooghe A; Wartel TA; Crevat D
Hum Vaccin Immunother; 2012 Sep; 8(9):1259-71. PubMed ID: 22894958
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines.
Santos J; Montellano ME; Solante R; Perreras N; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
Pediatr Infect Dis J; 2021 Sep; 40(9):856-863. PubMed ID: 34117198
[TBL] [Abstract][Full Text] [Related]
18. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Torresi J; Heron LG; Qiao M; Marjason J; Chambonneau L; Bouckenooghe A; Boaz M; van der Vliet D; Wallace D; Hutagalung Y; Nissen MD; Richmond PC
Vaccine; 2015 Sep; 33(39):5127-34. PubMed ID: 26279339
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
[TBL] [Abstract][Full Text] [Related]
20. Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule.
Coronel D; García-Rivera EJ; Rivera M; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Zhao J; Tila M; Jackson N; Zambrano B; Noriega F
Pediatr Infect Dis J; 2019 May; 38(5):e90-e95. PubMed ID: 30986790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]